Advertisement
Pharmaceutical Companies
Subscribe to Pharmaceutical Companies

The Lead

Daiichi Sankyo to Acquire Ambit Biosciences

September 29, 2014 10:15 am | News | Comments

Daiichi Sankyo Company and Ambit Biosciences, jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis.

FDA Approves Revised Indication for Allergan's OZURDEX®

September 29, 2014 10:06 am | News | Comments

Allergan announced today that the U.S. Food and Drug Administration (FDA) has approved OZURDEX...

M&A Update: Abbott, CFR, Pfizer, InnoPharma

September 26, 2014 11:07 am | News | Comments

Pfizer announced that it has completed its acquisition of pharmaceutical development company,...

Valeant Pharma Expects Third Quarter Revenue to Top Forecasts

September 24, 2014 1:07 pm | by The Associated Press | News | Comments

Shares of Valeant Pharmaceuticals International Inc. climbed Wednesday after the Canadian...

View Sample

FREE Email Newsletter

New FDA Label Bolsters Safety Case for Chantix

September 24, 2014 11:43 am | News | Comments

New government-approved labeling on Pfizer's drug Chantix suggests that the anti-smoking medication may not carry the risks of suicidal behavior that first earned it the government's strongest warning more than five years ago.    

Analyst: GSK's $490M Fine to Spark Pharma Strategy Shift in Emerging Markets

September 24, 2014 11:21 am | News | Comments

The scandal and its repercussions will be felt deep into Big Pharma’s operations in emerging markets, causing a fundamental shift in product marketing approaches involving physicians.           

SAFC and Baxter BioPharma Solutions to Collaborate on ADC Offering

September 24, 2014 11:16 am | News | Comments

SAFC will contribute extensive expertise in conjugation and the manufacture of drug linkers, while BioPharma Solutions will offer world-class, sterile fill/finish services for final filling of ADC products.        

Advertisement

Genzyme Collaborates on Gene Therapy for Rare Disease that Causes Childhood Blindness

September 24, 2014 8:32 am | News | Comments

Genzyme, a Sanofi company, today announced the establishment of a research collaboration with the University of Florida and the University of Pennsylvania to develop a gene therapy for the treatment of a rare genetic disease that causes childhood blindness.

Baxter and Merrimack Pharmaceuticals to Develop and Commercialize Cancer Compound

September 24, 2014 8:13 am | News | Comments

Baxter International and Merrimack Pharmaceuticals have announced an exclusive license and collaboration agreement for the development and commercialization of MM-398 (nanoliposomal irinotecan injection), also known as ''nal-IRI.''    

Pershing Capital Threatens to Sue Allergan if it Acquires Salix Without Vote

September 23, 2014 2:40 pm | by Ross Marowits, The Canadian Press | News | Comments

Allergan's largest shareholder, Pershing Square Capital, has threatened to sue the Botox maker if it attempts to buy Salix Pharmaceuticals without holding a shareholder vote. The investment fund headed by Bill Ackman has teamed up with Valeant Pharmaceuticals to make a $50-billion hostile takeover bid for Allergan.

Bristol-Myers Squibb to Build New Campus in Lawrenceville, NJ

September 23, 2014 12:33 pm | News | Comments

Bristol-Myers Squibb Company today announced plans to build a 650,000-square-foot office building on company-owned land at the intersection of Princeton Pike and Interstate 295 in Lawrenceville, New Jersey. Construction is expected to begin this fall and the new facility is expected to open by the end of 2016.

Biogen Idec Names Senior Vice President, Gene Therapy

September 23, 2014 9:09 am | News | Comments

Biogen Idec today announced that Olivier Danos, Ph.D., has joined the company as senior vice president, Gene Therapy. Dr. Danos reports directly to Douglas Williams, Ph.D., executive vice president, Research and Development, and is a member of Biogen Idec’s Senior Research and Development Leadership Team.

Advertisement

MedImmune Receives FDA Fast Track Designation for Development of MEDI3902 for Prevention of Nosocomial Pneumonia

September 23, 2014 8:22 am | News | Comments

AstraZeneca announced today that its global biologics research and development arm, MedImmune, has received fast track designation from the FDA for its investigational monoclonal antibody (mAb) MEDI3902 for the prevention of nosocomial pneumonia caused by Pseudomonas aeruginosa (P. aeruginosa), a highly drug-resistant bacterial pathogen.

Biogen Idec Named Global Biotechnology Industry Leader on Dow Jones Sustainability World Index

September 23, 2014 8:18 am | News | Comments

Biogen Idec has been named the biotechnology industry leader on the Dow Jones Sustainability World Index (DJSI World). The company also was named to the Dow Jones Sustainability Index (DJSI) North America for the fifth consecutive year, one of only two biotech companies included.

Amgen Submits BLA for Investigational BiTE Immunotherapy Blinatumomab

September 22, 2014 2:20 pm | News | Comments

The BLA is for the treatment of adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the blood and bone marrow. BiTE antibody constructs represent an innovative immunotherapy approach that helps the body's immune system target cancer cells.

Avalon Ventures and GlaxoSmithKline Launch Two New Companies

September 22, 2014 8:08 am | News | Comments

Silarus Therapeutics and Thyritope Biosciences each will receive up to $10M in Series A financing and R&D support from Avalon Ventures and GSK. Both companies will be located at COI Pharmaceuticals in San Diego, the community of innovation established by Avalon Ventures to provide operational support, a fully equipped R&D facility and an experienced leadership team to its life science portfolio companies.

Auxilium Pharma Rejects Endo's Takeover Offer

September 22, 2014 8:02 am | News | Comments

Auxilium, based in Chesterbrook, Pennsylvania, had adopted a one-year "poison pill" shareholder rights plan last week. The drugmaker continues to support its plan to combine with Canadian eye drugmaker QLT Inc. in an all-stock deal.    

Advertisement

Merck KGaA to Buy Sigma Aldrich for $17B

September 22, 2014 7:44 am | by David Mchugh - AP Business Writer - Associated Press | News | Comments

Merck says it has agreed to buy St. Louis-based chemical firm Sigma-Aldrich Corp. for $17 billion. Darmstadt-based Merck KGaA said Monday it is paying $140 per share in cash for all of Sigma-Aldrich's shares — a premium of 37 percent over Friday's closing price of $102.37.

China Fines GSK $492M for Bribery

September 19, 2014 5:47 am | by Joe Mcdonald - AP Business Writer - Associated Press | News | Comments

A former executive of drugmaker GlaxoSmithKline and four Chinese co-defendants have been sentenced to prison in a bribery case but may never have to serve that time. China's official Xinhua News Agency said Briton Mark Reilly and his Chinese co-defendants were given a three-year reprieve at their sentencing Friday.

FDA Approves Eli Lilly's Injectable Diabetes Drug

September 18, 2014 4:46 pm | by The Associated Press | News | Comments

The Food and Drug Administration has approved a new injectable diabetes drug from Eli Lilly and Co. for adults with the most common form of the disease. The agency on Thursday cleared the drug, Trulicity, as a weekly injection to improve blood sugar control in patients with type 2 diabetes.

Merck KGaA Strengthens Executive Board

September 18, 2014 2:20 pm | News | Comments

Merck KGaA today announced that the Board of Partners has promoted Stefan Oschmann to the position of Deputy CEO and Vice Chairman of the Executive Board. Concurrently, Belén Garijo was appointed to the Executive Board to take over leadership for the Pharma business.

Bayer to Split Off Polymer Division with IPO

September 18, 2014 7:45 am | by The Associated Press | News | Comments

German pharmaceuticals and chemicals company Bayer AG says it plans a separate stock listing for its polymer division. The Leverkusen-based company that invented aspirin said Thursday the move would be part of an effort to focus the group on its health care and crop science businesses.

Baxter Recalls One Lot of Potassium Chloride Injection

September 17, 2014 3:00 pm | News | Comments

Baxter International Inc. announced today it is voluntarily recalling one lot of Potassium Chloride Injection 10mEq per 100mL, product code 2B0826 to the hospital/pharmacy/nurse level. The recall is being initiated due to a labeling error on the shipping cartons in a single lot, which was identified by three customers.

First UK Volunteer Gets Experimental Ebola Vaccine

September 17, 2014 12:51 pm | by The Associated Press | News | Comments

British scientists say a former nurse has become the first person in the country to receive an experimental Ebola vaccine in an early trial to test its safety. Ruth Atkins, 48, got the injection on Wednesday in Oxford, the first of 60 healthy volunteers in the U.K. who will receive the vaccine.

Sun Pharma and Merck Announce $80M Licensing Agreement for Tildrakizumab

September 17, 2014 9:00 am | News | Comments

Merck and Sun Pharmaceutical Industries have announced an exclusive worldwide licensing agreement for Merck’s investigational therapeutic antibody candidate, tildrakizumab, (MK-3222), which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis.

EMD Serono and Sutro Biopharma Announce $298M Deal to Develop Antibody Drug Conjugates

September 17, 2014 8:14 am | News | Comments

EMD Serono and Sutro Biopharma announced a collaboration and license agreement to develop antibody drug conjugates (ADCs). ADCs are composed of an antibody linked to a cytotoxic drug. The antibody is thought to specifically target and deliver the cytotoxic drug to the cancer cells.

Endo Makes $1.4B Offer for Auxilium Pharma

September 16, 2014 5:45 pm | by The Associated Press | News | Comments

Endo International PLC says it is making an unsolicited offer for Auxilium Pharmaceuticals that values Auxilium at $28.10 per share. The deal is worth $1.41 billion in cash and stock, based on Auxilium's shares outstanding. Endo values the offer at $2.2 billion.

Big Cities Take Aim at Prescription Painkillers

September 16, 2014 2:25 pm | by MATTHEW PERRONE, AP Health Writer | News | Comments

Some of the nation's largest cities are ratcheting up their criticism of prescription painkillers, blaming the industry for a wave of addiction and overdoses that have ravaged their communities and busted local budgets.      

MedGenesis Enters Into Agreement with Pfizer for Potential Treatments for Parkinson's Disease

September 16, 2014 9:07 am | News | Comments

MedGenesis Therapeutix has entered into an agreement with Pfizer, granting Pfizer an exclusive, worldwide option to license its glial cell line-derived neurotrophic factor (GDNF) protein and convection enhanced delivery (CED) technology to be used in research for potential treatments for Parkinson's disease.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading